REG - Destiny Pharma PLC - Director/PDMR Shareholding

Destiny PharmaAnnouncement

19/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231019:nRSS5764Qa&default-theme=true

RNS Number : 5764Q  Destiny Pharma PLC  19 October 2023

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Director/PDMR Shareholding

 

Brighton, United Kingdom - 19 October 2023 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and treat life threatening
infections, announces that it was notified on 18 October 2023 that on 17
October 2023, Chris Tovey, Chief Executive Officer of the Company, transferred
30,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to
his wife and two daughters, all PCAs, by way of gift for nil consideration.

 

Following the transfer, Chris Tovey's beneficial interest in the Company
remains unchanged at 40,000 Ordinary Shares, representing 0.04 per cent. of
the total issued share capital.

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

 

For further information on the Company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86MTUzZTZjNTdkOGU2YTA4YmVjZDAzYzcwMmJmODM0ODk6NjozZThjOjBmMDE5MWJiMjJkOWNlOGRjY2RlMzE3MGMzNGEwZDBjMDJlMmMwNmI3ZmMzYjZiMWY3MjM4MDA2N2ZjM2Y5YTE6cDpU)

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under Article 17 of
MAR.

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.                                Details of the person discharging managerial responsibilities / person closely
                                   associated
 a)                                Name                                                         Chris Tovey
 2.                                Reason for the Notification
 a)                                Position/status                                              Chief Executive Officer
 b)                                Initial notification/Amendment                               Initial notification
 3.                                Details of the issuer, emission allowance market participant, auction
                                   platform, auctioneer or auction monitor
 a)                                Name                                                         Destiny Pharma plc
 b)                                LEI                                                          213800O9WH9Z38EHAC95
 4.                                Details of the transaction(s): section to be repeated for (i) each type of
                                   instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                                   place where transactions have been conducted
 a)                                Description of the Financial instrument, type of instrument  Ordinary shares of 1 pence each
                                   Identification code                                          DEST      GB00BDHSP575
 b)                                Nature of the transaction                                    Transfer of Ordinary Shares, by way of gift, to wife and daughters, Persons
                                                                                                Closely Associated with him, for nil consideration.
 c)                                Price(s) and volume(s)                                        0 (gift)

                                                                                                 30,000 Ordinary Shares
 d)                                Aggregated information:

                                   Aggregated volume                                            See 4c) above

                                   Price
 e)                                Date of the transaction                                      17 October 2023
 f)                                Place of the transaction                                     Off-Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEEILLTLIV